Merck And Korea's Hanmi Build On Cozaar Deal From One Country To More Than 30, And More Could Be On The Way
By
Pharmasia News / PharmAsia News Jun. 10, 2011 10:00 AM GMT
Asia / Word Count: 651 / Article # 28110610001
Executive Summary
SEOUL - Merck & Co. Inc.'s emphasis on lifecycle management for its Cozaar brand is good news for Hanmi Pharmaceutical, as Merck recently expanded a marketing rights deal for Hanmi's ARB/CCB combination that pairs amlodipine with Merck's losartan. A deal that started in 2009 for the Korean market now stands at 30 markets and signs point to an even broader deal in the future
$35.00
Buy Now
For $35.00, purchase this 651-word article and receive immediate online access. 100% Satisfaction Guarantee.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.